Tag Archives: Covid-19 vaccine

More Good News on Vaccines

Happy Hump Day! This info is very encouraging. Maybe we’re close to turning the corner on this vicious pandemic. How sad it didn’t happen much, much earlier. And if Congress defangs that crazy Marjorie Taylor Greene, it will be an all-around excellent week. Cheers!

[From New York Times]
“For once, we have some good news to talk about: the prospect of another vaccine coming online in the U.S., and a long-awaited indication that at least one vaccine reduces transmission, not just the severity of Covid-19.

Let’s start with the remarkable turnaround of the experimental vaccine from Novavax, a Maryland-based company that has never before brought a vaccine to market.

Last fall, Novavax postponed U.S. clinical trials because of manufacturing delays, jeopardizing the company’s $1.6 billion federal contract and leaving some to wonder whether they should write off the company’s shot entirely. In December, Novavax watched from the sidelines as the Pfizer-BioNTech and Moderna vaccines were approved.

But things have changed. Novavax announced last week that its vaccine produced robust protection in a large British trial and that it worked — although far less well — in a smaller study in South Africa. The company has also been able to quickly recruit volunteers for its U.S. trials because the two authorized vaccines have been difficult to get, and many see the Novavax trial as their best chance to get vaccinated.

So the company now stands a chance of having trial results this spring, with possible government authorization as early as April. If everything goes well, and that is a big if, Novavax could deliver enough additional doses to vaccinate 55 million Americans by the end of June. That would be on top of the 400 million doses that Moderna and Pfizer are contracted to supply the U.S. by the middle of the year — enough for 200 million people.

It gets better: Novavax has been laying the international groundwork for the eventual production of two billion doses per year — and its vaccine, unlike Moderna and Pfizer’s, can be stored and shipped at normal refrigeration temperatures.

As for protection against transmission, AstraZeneca recently released a report that offered an answer to one of the pandemic’s big questions: Will vaccines prevent people from giving the virus to others?

Researchers from the University of Oxford and AstraZeneca have found that not only did their vaccine protect people from serious illness and death but also had the potential to reduce transmission. Swabs taken from trial participants showed a 67 percent reduction in virus being detected among those vaccinated, though scientists warned that the data was preliminary and that masking remained necessary for all.

The AstraZeneca-Oxford vaccine is in U.S. trials, and the company has a deal to supply 300 million doses, enough for another 150 million people.”

Good News Monday: Beginning of the End?

The first coronavirus vaccine was given in the U.S., opening a new, hopeful chapter in the battle against a pandemic that has ravaged the country.
Monday, December 14, 2020 9:35 AM EST
Shortly after 9 a.m. on Monday, vaccinations took place in Long Island Jewish Medical Center in Queens, N.Y. The pandemic has scarred New York State profoundly, leaving more than 35,000 people dead and severely weakening the economy.
The vaccinations started after the Food and Drug Administration’s emergency authorization of the Pfizer-BioNTech vaccine on Friday night, and as the U.S. coronavirus death toll approaches 300,000, with a steady surge in new cases daily.
Better late than never?
Photo by Karolina Grabowska on Pexels.com

Good News Monday: Full Speed Ahead

No time for an original post today, but want to share this encouraging article from my daily New York Times email briefing:

A running start for a vaccine at Oxford

Here’s promising news in the worldwide race to develop a vaccine to ward off the coronavirus. The Jenner Institute at Oxford University has one that seems to work in lab animals and is ready to test its effectiveness in humans, if regulators approve.

The institute had a big head start, our correspondent David D. Kirkpatrick reports. Its scientists had an approach that they already knew was safe: They had proved it in trials last year for a vaccine to fight MERS, a respiratory disease caused by a closely related virus.

That has enabled the institute to skip ahead and schedule tests of its new Covid-19 vaccine on more than 6,000 people by the end of May, hoping to show not only that it is safe, but also that it works.

Scientists at the National Institutes of Health’s Rocky Mountain Laboratory in Montana got very good results when they tried out the Oxford vaccine last month on six rhesus macaque monkeys. The animals were then exposed to heavy quantities of the coronavirus. After more than four weeks, all six were still healthy.

“The rhesus macaque is pretty much the closest thing we have to humans,” said Vincent Munster, the researcher who conducted the test.

Immunity in monkeys doesn’t guarantee that a vaccine will protect people, but it’s an encouraging sign. If the May trials go well and regulators grant emergency approval, the Oxford scientists say they could have a few million doses of their vaccine available by September — months ahead of other vaccine projects.

“It is a very, very fast clinical program,” said Emilio Emini of the Bill and Melinda Gates Foundation, which is helping to finance a number of competing efforts.

All in the genes: The Jenner Institute isn’t following the classic approach of using a weakened version of the disease pathogen. Instead, its approach starts with another familiar virus, neutralizes it and then genetically modifies it so that it will prompt the body to produce the right antibodies for Covid-19.

Researchers originally cooked up the technology in a quest to develop a vaccine for malaria, which is caused by a parasite. No luck there yet. But when the idea was borrowed to go after MERS, it worked well.

woman in blue tank top smiling

Photo by Andrea Piacquadio on Pexels.com